Collins Stewart: United Therapeutics Reiterates FY12/FY13 Revenue Guidance, Despite 4Q11 Miss

In a research report published earlier today by Collins Stewart, United Therapeutics UTHR reported 4Q11 total revenues of $195.2M this morning, below Street consensus of $204.8M. According to Collins Stewart, “4Q11 GAAP EPS was $0.77, also below consensus of $0.87 and CSe of $0.84, with lower revenue and higher stock-based compensation partially offset by lower tax expense. The company reiterated its FY12 revenue guidance of $831M to $919M (vs. consensus of $880.3M and CSe of $896.2M) and its FY13 revenue guidance of $950M to $1.1B (vs. consensus of $982.2M and CSe of $999.8M).” Collins Stewart maintains its Buy rating and $56 PT on United Therapeutics, which closed yesterday at $49.26.
Market News and Data brought to you by Benzinga APIs
Comments
Loading...
date
ticker
name
Price Target
Upside/Downside
Recommendation
Firm
Posted In: Analyst ColorReiterationAnalyst RatingsCollins Stewart
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!